Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Provided By GlobeNewswire
Last update: May 14, 2024
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated
Secured Global Development and Commercial Rights to Levosimendan for Treatment of PH-HFpEF
Read more at globenewswire.com
